ICYMI: FDA Approves INOVIO’s First DNA Medicine for Rare Disease
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) recently secured accelerated approval from the U.S. Food and Drug Administration for VOCERYQ, the first FDA-approved DNA medicine, giving adults with recurrent respiratory …
ICYMI: FDA Approves INOVIO’s First DNA Medicine for Rare Disease Read More